Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q1 2014 · 10-Q
Revenue—
Net Income-$2.63M-$2.63MN/M vs Q1 2013 EPS Diluted-$0.29-$0.29N/M vs Q1 2013 Operating Income-$2,628,000N/M Operating Cash Flow-$2,624,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
ended Mar 31, 2014 · filed May 8, 2014 · 38 d after period end